News

Sun Pharma Q1 FY27: Revenue ₹15,300 Crore, Profit Up 27% — India Business at 16%, Innovative Medicines at 12.8%, and Organon on Track for Q4

By Mustafa Shariff, Editor in Chief · Aug 04,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Sun Pharma Q1 FY27: Revenue ₹15,300 Crore, Profit Up 27% — India Business at 16%, Innovative Medicines at 12.8%, and Organon on Track for Q4

Summary

: Sun Pharma Q1 FY27: ₹15,300 Crore Revenue (+10.5%), 27% Profit Rise — India +16%, Innovative Medicines +12.8%, Organon on Track for Q4 FY27
Sun Pharma reported Q1 FY27 consolidated revenue of ₹15,300 crore (+10.5%), net profit ₹2,895 crore (+27%), India formulations +16%, Global Innovative Medicines +12.8% — with Organon acquisition on track for Q4 FY27 close.

"Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027. We are well positioned to deliver high single-digit revenue growth for the full year."

Sun Pharmaceutical Industries Limited, India's largest pharmaceutical company by revenue, reported its consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27) on July 31, 2026. Consolidated revenue from operations reached ₹15,300 crore, up 10.5% year-on-year from ₹13,851 crore in Q1 FY26. Net profit attributable to owners rose 27% year-on-year to ₹2,895 crore, from ₹2,279 crore in the prior year period. Adjusted net profit — which excludes acquisition-related and other exceptional items — rose 3.1% to ₹3,089 crore.

EBITDA reached ₹4,418 crore, up 2.7% year-on-year, with EBITDA margin contracting 220 basis points to 28.9% from 31.1% in Q1 FY26. The margin contraction reflects one-time acquisition-related costs associated with the Organon transaction — a temporary headwind that management has flagged will continue until the deal closes, which is now on track for the fourth quarter of FY27.

India Business: Record Momentum
Sun Pharma's India formulations business delivered its strongest quarterly performance in recent years: India sales of ₹5,475 crore, up 16% year-on-year, representing 36.1% of total consolidated sales. Sun Pharma's market share in the Indian Pharmaceutical Market improved to 8.5% per the Pharmarack MAT June 2026 report, up from 8.2% — extending the company's position as India's most prescribed pharmaceutical company across 12 doctor categories per the SMSRC report. The India business launched 5 new products during the quarter.

The 16% India growth is substantially above the 13.3% Indian Pharmaceutical Market growth rate that Pharmarack reported for June 2026 (covered BHC Media July 27 edition) — confirming Sun Pharma is growing market share, not just growing with the market.

Global Innovative Medicines: The Strategic Priority
Global Innovative Medicines — the segment that includes Sun Pharma's specialty pharmaceutical products like dermatology biologic Ilumya (tildrakizumab), ophthalmology drug Cequa, Winlevi, and other branded specialty products marketed in the US and internationally — generated $351 million in Q1 FY27, up 12.8% year-on-year. Innovative Medicines now accounts for 21.9% of total consolidated sales, confirming Sun Pharma's deliberate transition from pure generics volume toward specialty pharmaceutical value.

Kirti Ganorkar, Managing Director, connected the Innovative Medicines growth to Sun Pharma's broader capability signal: recent semaglutide approvals in India, Brazil, and South Africa underscore capabilities in developing complex peptide products for patients globally — framing Sun Pharma's semaglutide generics success not just as a market opportunity but as a demonstration of the complex pharmaceutical development capability that its Innovative Medicines pipeline builds upon.

US Generics: Continued Pressure
US formulations sales were $427 million, down 9.7% year-on-year — a continuation of the challenging dynamics in the US generic pharmaceutical market that multiple Indian pharmaceutical companies have navigated in 2026. Cipla's North America business showed steady momentum (covered July 27 edition), while Sun Pharma's US generics faced pricing pressure offset partially by Innovative Medicines growth. Sun Pharma has 558 approved ANDAs in the US, with 119 applications awaiting approval including 28 with tentative approvals.

Organon Acquisition: Shareholders Approve, Q4 FY27 Close
The most strategically significant disclosure in the Q1 FY27 results is the confirmation that Organon shareholders have approved the proposed acquisition by Sun Pharma, with the deal on track to close in the fourth quarter of FY27 (January-March 2027). BHC Media has covered the Sun Pharma-Organon deal — at $11.75 billion, the largest outbound acquisition by an Indian pharmaceutical company — since its announcement (June 11 edition). Dilip Shanghvi, Chairman, noted that regulatory filings across various markets have been completed, approvals already received in some countries, and an integration management office has been working on day-one preparedness.

BHC Perspective
At Bengaluru Health Community, Sun Pharma's Q1 FY27 results are a case study in what India's Great Pharma Pivot looks like in practice: India growing 16%, Innovative Medicines growing 12.8%, Organon closing Q4 FY27, and semaglutide approvals across three markets demonstrating complex peptide development capability. For BHC founders in pharmaceutical innovation, specialty medicine, or global market access — Sun Pharma's Q1 FY27 is the destination that the Great Pharma Pivot strategy is building toward.

Frequently Asked Questions
Q: What were Sun Pharma's Q1 FY27 results?
A: Consolidated revenue ₹15,300 crore (+10.5% YoY). Net profit ₹2,895 crore (+27% YoY). EBITDA ₹4,418 crore (+2.7%), margin 28.9% (-220 bps from acquisition costs). India formulations ₹5,475 crore (+16%, market share 8.5%). Global Innovative Medicines $351M (+12.8%). US generics $427M (-9.7%).

Q: What is the Organon acquisition status?
A: Organon shareholders have approved the Sun Pharma acquisition. Deal on track to close in Q4 FY27 (January-March 2027). Regulatory filings completed across various markets, approvals received in some countries. Integration management office working on day-one preparedness.

Q: What is Sun Pharma's FY27 guidance?
A: High single-digit revenue growth for FY27, maintained despite reporting 10.1% Q1 growth. Acquisition-related expenses expected to continue in coming quarters, with substantial portion expected closer to Organon transaction completion.